Lanabecestat

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLanabecestat
Drug Alias NameBACE inhibitor - AstraZenecaBeta secretase inhibitor - AstraZenecaLY-3314814AZD-3293
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-secretase 1 inhibitors
TargetsBeta-secretase 1
Therapy Area/IndicationsRenal InsufficiencyAlzheimer DiseaseHepatic Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[24] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyAstrazeneca AbEli Lilly Asia Shanghai Representative Office
Inactive CompaniesAstrazeneca Plc
Active IndicationsAlzheimer Disease
Inactive IndicationsRenal InsufficiencyHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksWikipedia